TY  - GEN
A1  - Hocher, Berthold
A1  - Yin, Lianghong
T1  - Why Current PTH Assays Mislead Clinical Decision Making in Patients with Secondary Hyperparathyroidism
T2  - Nephron
N2  - Preclinical studies in cell culture systems as well as in whole animal chronic kidney disease (CKD) models showed that parathyroid hormone (PTH), oxidized at the 2 methionine residues (positions 8 and 18), caused a loss of function. This was so far not considered in the development of PTH assays used in current clinical practice. Patients with advanced CKD are subject to oxidative stress, and plasma proteins (including PTH) are targets for oxidants. In patients with CKD, a considerable but variable fraction (about 70 to 90%) of measured PTH appears to be oxidized. Oxidized PTH (oxPTH) does not interact with the PTH receptor resulting in loss of biological activity. Currently used intact PTH (iPTH) assays detect both oxidized and non-oxPTH (n-oxPTH). Clinical studies demonstrated that bioactive, n-oxPTH, but not iPTH nor oxPTH, is associated with mortality in CKD patients.
KW  - Serum intact-parathyroid hormone level
KW  - Dialysis patients
KW  - Mortality
Y1  - 2017
U6  - https://doi.org/10.1159/000455289
SN  - 1660-8151
SN  - 2235-3186
SN  - 0028-2766
VL  - 136
IS  - 2
SP  - 137
EP  - 142
PB  - Karger
CY  - Basel
ER  -